{"result": "(\"entity\"<|>TOMAS DE TOLVAPTÁN<|>EVENT<|>The administration of tolvaptán is a medical treatment advised to be taken without water.)\n##\n(\"entity\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>EVENT<|>SIADH is a syndrome characterized by excessive secretion of antidiuretic hormone, leading to water retention and hyponatremia.)\n##\n(\"entity\"<|>SISTEMA NERVIOSO CENTRAL<|>ORGANIZATION<|>The central nervous system can be affected by various conditions that may lead to SIADH.)\n##\n(\"entity\"<|>TUMORES<|>EVENT<|>Tumors can be a cause of SIADH due to ectopic production of vasopressin.)\n##\n(\"entity\"<|>ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA<|>EVENT<|>Chronic obstructive pulmonary disease is a condition that can contribute to the development of SIADH.)\n##\n(\"entity\"<|>QUIMIOTERÁPICOS<|>EVENT<|>Chemotherapeutic agents are known to be associated with SIADH due to their effects on hormone secretion.)\n##\n(\"relationship\"<|>TOMAS DE TOLVAPTÁN<|>SIADH<|>The administration of tolvaptán is indicated in the treatment of SIADH<|>7)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>FLUOXETINA<|>Fluoxetina is associated with the development of SIADH<|>7)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>CLORPROPAMIDA<|>Clorpropamida is recognized as a medication that can cause SIADH<|>6)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>CARBAMACEPINA<|>Carbamacepina is known to contribute to the occurrence of SIADH<|>6)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>TUMORES<|>Tumors can lead to SIADH through ectopic vasopressin production<|>5)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>ENFERMEDAD PULMONAR OBSTRUCTIVA CRÓNICA<|>Chronic obstructive pulmonary disease can be a contributing factor to SIADH<|>5)\n##\n(\"relationship\"<|>SÍNDROME DE SECRECIÓN INAPROPIADA DE LA HORMONA ANTIDIURÉTICA<|>QUIMIOTERÁPICOS<|>Chemotherapeutic agents are associated with the development of SIADH<|>5)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: C. Al inicio de la toma de tolvaptán se aconseja que no ingieran agua.\n        D.   En una situación aguda en coma y con convulsiones está indicado la administración\n             de 100 ml de ClNa al 3% y repetir en 30 min si no se produce mejoría clínica.\n\n\n\n68                                                                                                                                                                                                                                                                             69\n---\n                                                                                                                                                                                                       HIPÓFISIS                         1\n\n\n\n    57  ¿Cuál de los siguientes fármacos puede dar lugar a un aumento de la liberación                            Los inhibidores de la recaptación de serotonina, como la fluoxetina, se asocian a SIADH,\n        o efecto de la ADH?                                                                                       sobre    todo   en mayores de 65 años (respuesta A). La carbamacepina y la                          clorpropamida\n                                                                                                                  también son causa reconocida de este síndrome (respuestas B y C).\n        A. Fluoxetina.\n        B. Clorpropamida.                                                                                         Referencias:\n                                                                                                                  • Sterns RH. Pathophysiology and etiology of the syndrome of inappropiate antidiuretic hormone secretion (SIADH). En: Emmett M,\n        C. Carbamacepina.                                                                                           Forman JP, eds. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com (acceso 29 de abril de 2019).\n                                                                                                                  • Villabona C. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015.\n        D.  Todas las opciones son correctas.                                                                       Capítulo 20. Síndrome de secreción inapropiada de la hormona antidiurética (SIADH) [citado 29 de abril de 2019]. Disponible en:\n                                                                                                                    https://manual.seen.es/article?id=55114bd4-c9f0-42b4-ac84-2bcdac18103c\n\n\n\n        COMENTARIO\n        Causas de SIADH                                                                                  1.11 Casos clínicos. Caso clínico 1\n        Las múltiples etiologías del SIADH se pueden agrupar en cinco categorías:\n          1. Tumoral: por producción ectópica de vasopresina. El carcinoma pulmonar de células             58     La forma de presentación del cuadro clínico le parece compatible con:\n              pequeñas es el más frecuente, seguido por los carcinomas de cabeza y cuello.                        A. Tumoración hipofisaria.\n          2. Patología del sistema nervioso central: tumoral, hemorrágica o isquémica, infecciosa,                B. Enfermedad Addison.\n              etc.                                                                                                C. Neurosarcoidosis.\n          3. Patología pulmonar: tumores, infecciones, asma, enfermedad pulmonar obstructiva                      D.  Hipofisitis autoinmune.\n              crónica.\n          4. Fármacos.                                                                                            COMENTARIO\n          5. Miscelánea: asociado al postoperatorio, dolor, náusea, retención urinaria, ejercicio ex-             La paciente presenta clínica (hipoglucemia y astenia) y datos bioquímicos (cortisol bajo)\n              tremo, o idiopático (ancianos).                                                                     compatibles con insuficiencia suprarrenal.\n        Los fármacos son una causa frecuente de SIADH, principalmente los psicótropos y quimio-                   Para    diferenciar     si  se  trata   de   una    insuficiencia     suprarrenal      primaria     o  secundaria,\n        terápicos. Algunos producen SIADH por estimulación directa de la liberación de vasopresi-                 el dato que nos puede orientar en este caso es la coloración de la piel. Si se tratase\n        na, y otros por aumento de su acción.                                                                     de una enfermedad de Addison o insuficiencia adrenal primaria, lo esperable sería encon-\n        Los fármacos más habitualmente relacionados con el SIADH serían:                                          trar hiperpigmentación          cutáneo-mucosa.          Esto   hace que nos inclinemos por una insufi-\n                                                                                                                  ciencia suprarrenal secundaria, es decir, por déficit de ACTH. Por tanto, descartaríamos\n        •  Antidepresivos: inhibidores selectivos de la recaptación de serotonina, tricíclicos, inhibi-           la opción B.\n           dores de la monoaminooxidasa, venlafaxina.                                                             El resto de las opciones entrarían en el diagnóstico diferencial de la insuficiencia supra-\n        •  Antiepilépticos: carbamacepina, valproato, lamotrigina.                                                rrenal secundaria. Pero el patrón hormonal que tiene la paciente también es útil en el\n        •  Antipsicóticos: fenotiazinas, butirofenonas.                                                           diagnóstico diferencial.\n        •  Quimioterápicos; alcaloides derivados de la vinca, platino, ifosfamida, melfalán, ciclo\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>FLUOXETINA<|>PERSON<|>Fluoxetina is an antidepressant that is associated with SIADH, particularly in individuals over 65 years old.)\n##\n(\"entity\"<|>CLORPROPAMIDA<|>PERSON<|>Clorpropamida is a medication recognized as a cause of SIADH.)\n##\n(\"entity\"<|>CARBAMACEPINA<|>PERSON<|>Carbamacepina is an antiepileptic drug that can lead to SIADH.)\n##\n(\"entity\"<|>SIADH<|>EVENT<|>SIADH, or Syndrome of Inappropriate Antidiuretic Hormone Secretion, is a condition characterized by excessive release of antidiuretic hormone.)\n##\n(\"entity\"<|>CORTISOL<|>PERSON<|>Cortisol is a hormone whose levels are measured to assess adrenal insufficiency.)\n##\n(\"entity\"<|>ACTH<|>PERSON<|>Adrenocorticotropic hormone (ACTH) is a hormone that stimulates the adrenal glands to produce cortisol.)\n##\n(\"entity\"<|>ENFERMEDAD ADDISON<|>EVENT<|>Addison's disease is a condition that leads to insufficient production of cortisol.)\n##\n(\"entity\"<|>INSUFICIENCIA SUPRARENAL<|>EVENT<|>Adrenal insufficiency is a condition where the adrenal glands do not produce adequate amounts of steroid hormones.)\n##\n(\"relationship\"<|>FLUOXETINA<|>SIADH<|>Fluoxetina is associated with the development of SIADH, especially in older adults<|>7)\n##\n(\"relationship\"<|>CLORPROPAMIDA<|>SIADH<|>Clorpropamida is recognized as a medication that can cause SIADH<|>6)\n##\n(\"relationship\"<|>CARBAMACEPINA<|>SIADH<|>Carbamacepina is known to contribute to the occurrence of SIADH<|>6)\n##\n(\"relationship\"<|>CORTISOL<|>INSUFICIENCIA SUPRARENAL<|>Cortisol levels are used to diagnose adrenal insufficiency<|>8)\n##\n(\"relationship\"<|>ACTH<|>INSUFICIENCIA SUPRARENAL<|>ACTH levels help differentiate between primary and secondary adrenal insufficiency<|>8)\n##\n(\"relationship\"<|>ENFERMEDAD ADDISON<|>INSUFICIENCIA SUPRARENAL<|>Addison's disease is a form of adrenal insufficiency<|>9)\n<|COMPLETE|>"}]}